• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NIBSC signs agreement with UCL

NIBSC signs agreement with UCL

October 2, 2014
CenterWatch Staff

A memorandum of understanding has been signed between the National Institute for Biological Standards and Control and University College London (UCL). The memorandum states that both parties should share common goals to help safeguard and enhance public health in the U.K. and elsewhere. Best available science should be applied to the international harmonization of standards for characterization, production and distribution, and the availability of cell lines and other key materials of appropriate quality for research and clinical use should be facilitated.

Professor Mary Collins, head of the advanced therapies at NIBSC, said, “Advanced therapies such as stem cell treatments have huge potential in directly targeting and treating a range of conditions. This link up with University College London will greatly help to take forward studies into the properties and potential therapeutic applications of advanced therapies.”

A steering group will be created made up of a principal and associate from NIBSC and UCL with the remit of:

  • Harmonizing standards for gene therapy, stem cell therapy and tissue engineering characterization, production and distribution
  • Providing thought leadership in safety and efficacy of gene therapy, stem cell therapy and tissue engineering
  • Identify opportunities for research projects that will lead to joint publications
  • Support staff exchange visits and secondments to develop research collaborations and share best practice
  • Run joint MSc courses, support Ph.D. students and continued professional development in relevant areas.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing